Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Novel Approach To Her2 Quantification Using Phosphor-integrated Dots In Human Breast Invasive Cancer Microarray.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Novel Approach To Her2 Quantification Using Phosphor-integrated Dots In Human Breast Invasive Cancer Microarray.

Related Experiment Video

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.

Naoya Saito1, Tsukasa Matsuo1, Hitoshi Tsuda2

  • 1Technology Development Headquarters, Advanced Core Technology Center, Konica Minolta, Inc., Hachioji, Japan.

Plos One
|May 15, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Phosphor-integrated dot (PID) immunostaining combined with whole slide imaging (WSI) quantitatively assesses HER2 expression in breast cancer. This digital analysis aids in stratifying HER2 immunohistochemistry (IHC) and classifying low HER2 expression.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.3K

Related Experiment Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.3K

Area of Science:

  • Oncology
  • Pathology
  • Biotechnology

Background:

  • Accurate HER2 (Human Epidermal growth factor Receptor 2) expression assessment is crucial for selecting breast cancer patients for anti-HER2 targeted therapies.
  • The development of new HER2-targeted drugs for low HER2 expression breast cancer necessitates a comprehensive understanding of the entire spectrum of HER2 expression.
  • Current immunohistochemistry (IHC) methods may require enhanced quantitative analysis for precise HER2 evaluation, especially in borderline cases.

Purpose of the Study:

  • To quantitatively assess HER2 expression in invasive breast cancer using a novel approach combining phosphor-integrated dot (PID) immunostaining and whole slide imaging (WSI).
  • To evaluate the correlation between PID-based quantitative HER2 assessment and traditional ASCO/CAP guideline-based IHC scoring.
  • To determine the utility of digital image analysis for stratifying HER2 IHC and classifying low HER2 expression.

Main Methods:

  • A 170-core tissue microarray of invasive breast cancer was utilized.
  • HER2 expression was assessed using two methods: standard immunohistochemistry (IHC) scored by pathologists and quantitative analysis of PID-stained samples.
  • Whole slide imaging (WSI) was employed for digital analysis of PID immunostaining.

Main Results:

  • Phosphor-integrated dot (PID) immunostaining allowed for numerical classification of HER2 expression into scores 3+, 2+, 1+, and 0.
  • The HER2 values quantified by PID showed a strong correlation with the 3,3'-diaminobenzidine (DAB) IHC scores determined by pathologists (R² = 0.93).
  • PID analysis revealed that cases with low HER2 expression (DAB IHC score 0) were sometimes classified as PID IHC score 1+, suggesting improved sensitivity for detecting low expression.

Conclusions:

  • Digital image analysis combining PID immunostaining and WSI provides a robust quantitative method for assessing HER2 expression in breast cancer.
  • This approach can effectively stratify HER2 IHC results and offers potential for more accurate classification of low HER2 expression.
  • The findings support the use of PID and WSI as valuable tools for enhancing HER2 assessment in clinical practice, particularly with the emergence of new targeted therapies.